Submitted by Anonymous (not verified) on 8 March 2024 - 15:02
Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0421/2019
Source: